MicroDose Therapeutx (formerly MicroDose Technologies Inc) Announces Conclusion of MDT-637 Phase I Single and Multiple Ascending Dose Studies in Healthy Volunteers for Treatment of Respiratory Syncytial Virus (RSV)

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--MicroDose Therapeutx, Inc. announced today that it has concluded the second of two Phase I studies with its novel inhaled antiviral fusion inhibitor, MDT-637, for the treatment of RSV infection. MicroDose has completed two double-blind, randomized, placebo-controlled dose-ranging studies in healthy volunteers assessing the pharmacokinetics, safety and tolerability of MDT-637 after single (Study MDT-637-CP-101) and multiple ascending doses (Study MDT-637-CP-102) of inhaled MDT-637 from MicroDose’s novel dry powder nebulizer technology.